Literature DB >> 1531910

Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease.

G J Harris1, G D Pearlson, C E Peyser, E H Aylward, J Roberts, P E Barta, G A Chase, S E Folstein.   

Abstract

The characteristic pathological features of Huntington's disease (HD) are neostriatal atrophy and neuronal loss. Although neuroradiological studies often show caudate atrophy in patients with moderate HD, frequently no caudate atrophy is found early in the illness. There have been no quantitative reports to date on in vivo putamen volume measures in mild HD, although the structure is known to be neuropathologically involved in the illness. We measured volumes of caudate nucleus and putamen and bicaudate ratios (BCR) from magnetic resonance images, blind to diagnosis, in 15 patients with mild HD and 19 age- and sex-matched control subjects using a computerized image analysis system. The region showing greatest atrophy was the putamen, which was reduced 50.1% in mean volume in HD patients compared with control subjects (p less than 0.000001). In contrast, caudate volume was reduced 27.7% (p = 0.004). BCR was increased 28.5% in HD patients (p = 0.0002). Discriminant function analysis was 94% effective in identifying the diagnostic group based on putamen volume alone, whereas caudate measures had considerable overlap. Correction of putamen volume for head size led to 100% separation by group. Putamen measures and BCR correlated with neurological examination scores but caudate volume did not. Volumetric measurement of putamen is a more sensitive indicator of brain abnormalities in mild HD than measures of caudate atrophy.

Entities:  

Mesh:

Year:  1992        PMID: 1531910     DOI: 10.1002/ana.410310113

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  28 in total

1.  Stability of resting fMRI interregional correlations analyzed in subject-native space: a one-year longitudinal study in healthy adults and premanifest Huntington's disease.

Authors:  Tyler M Seibert; D S Adnan Majid; Adam R Aron; Jody Corey-Bloom; James B Brewer
Journal:  Neuroimage       Date:  2011-09-10       Impact factor: 6.556

Review 2.  Brain imaging and cognitive dysfunctions in Huntington's disease.

Authors:  Alonso Montoya; Bruce H Price; Matthew Menear; Martin Lepage
Journal:  J Psychiatry Neurosci       Date:  2006-01       Impact factor: 6.186

3.  Longitudinal diffusion changes in prodromal and early HD: Evidence of white-matter tract deterioration.

Authors:  Joseph J Shaffer; Ali Ghayoor; Jeffrey D Long; Regina Eun-Young Kim; Spencer Lourens; Lauren J O'Donnell; Carl-Fredrik Westin; Yogesh Rathi; Vincent Magnotta; Jane S Paulsen; Hans J Johnson
Journal:  Hum Brain Mapp       Date:  2017-01-03       Impact factor: 5.038

4.  Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study.

Authors:  Kevin M Biglan; Christopher A Ross; Douglas R Langbehn; Elizabeth H Aylward; Julie C Stout; Sarah Queller; Noelle E Carlozzi; Kevin Duff; Leigh J Beglinger; Jane S Paulsen
Journal:  Mov Disord       Date:  2009-09-15       Impact factor: 10.338

5.  Imaging of Huntington's disease.

Authors:  R S Negi; K L Manchanda; Sunil Sanga
Journal:  Med J Armed Forces India       Date:  2012-10-23

6.  Regional specificity of sex effects on subcortical volumes across the lifespan in healthy aging.

Authors:  Wenjing Li; Marie-José van Tol; Meng Li; Wen Miao; Yonghong Jiao; Hans-Jochen Heinze; Bernhard Bogerts; Huiguang He; Martin Walter
Journal:  Hum Brain Mapp       Date:  2012-09-21       Impact factor: 5.038

Review 7.  An overview of psychiatric symptoms in Huntington's disease.

Authors:  K E Anderson; K S Marder
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

8.  Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington's disease.

Authors:  T M Tsang; J N Haselden; E Holmes
Journal:  Neurochem Res       Date:  2009-01-16       Impact factor: 3.996

9.  Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease.

Authors:  G Sedvall; P Karlsson; A Lundin; M Anvret; T Suhara; C Halldin; L Farde
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

Review 10.  Magnetic resonance imaging of Huntington's disease: preparing for clinical trials.

Authors:  S Klöppel; S M Henley; N Z Hobbs; R C Wolf; J Kassubek; S J Tabrizi; R S J Frackowiak
Journal:  Neuroscience       Date:  2009-01-29       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.